Knight Therapeutics Inc. GUD.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 43.62% | 37.86% | 19.11% | 15.67% | 10.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.62% | 37.86% | 19.11% | 15.67% | 10.60% |
| Cost of Revenue | 32.57% | 35.61% | 24.71% | 28.50% | 22.16% |
| Gross Profit | 58.29% | 40.60% | 12.79% | 1.91% | -1.74% |
| SG&A Expenses | 32.24% | 26.98% | 19.25% | 15.79% | 12.69% |
| Depreciation & Amortization | 37.85% | 28.03% | 9.61% | 0.62% | -9.53% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.84% | 33.04% | 21.24% | 21.46% | 14.83% |
| Operating Income | 602.19% | 3,762.91% | -83.89% | -175.34% | -164.60% |
| Income Before Tax | 381.99% | -9.49% | -478.82% | 68.90% | 68.39% |
| Income Tax Expenses | 183.78% | 207.88% | 45.36% | -391.07% | -204.87% |
| Earnings from Continuing Operations | 8,127.81% | -47.98% | -236.11% | 88.13% | 100.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8,127.81% | -47.98% | -236.11% | 88.13% | 100.84% |
| EBIT | 602.19% | 3,762.91% | -83.89% | -175.34% | -164.60% |
| EBITDA | 109.60% | 57.19% | -7.33% | -26.97% | -27.67% |
| EPS Basic | 18,083.33% | -46.04% | -235.14% | 87.40% | 100.39% |
| Normalized Basic EPS | 493.87% | 6,288.89% | -175.59% | -205.42% | -211.51% |
| EPS Diluted | 1,446.15% | -50.14% | -285.25% | 83.24% | 95.02% |
| Normalized Diluted EPS | 492.90% | 6,255.56% | -175.59% | -205.42% | -211.51% |
| Average Basic Shares Outstanding | -1.32% | -1.38% | -1.46% | -1.94% | -2.80% |
| Average Diluted Shares Outstanding | -1.28% | -1.34% | -1.32% | -1.73% | -2.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |